Medtronic India, a global medical technology company has launched a series of cardiac care products, EnPulse pacemaker, EnRhythm pacemaker (dual-chamber), EnTrust implantable cardioverter-defibrillators (ICDs) (single- and dual-chamber versions) and InSync Sentry cardiac resynchronisation therapy defibrillator (CRT-D). All three products are expected to add value to the physician’s diagnosis and treatment options for specific heart disorders.

EnRhythm and EnTrust are part of Medtronic’s Physiologic Pacing Programme, a comprehensive initiative focused on providing tailored solutions to promote a patient’s normal cardiac function. The former is an ideal pacemaker for abnormally slow heart rhythm (bradycardia) due to sinus node dysfunction or intermittent AV block. The EnTrust ICD is for those at risk of developing abnormally fast and potentially life-threatening heartbeats (tachycardia) that can lead to sudden cardiac arrest. The dual-chamber EnTrust device also is indicated to treat atrial tachyarrhythmias.

The EnPulse pacemaker is the first-ever fully automatic pacemaker with advanced device features to automatically fine-tune therapy for patients whose hearts beat too slowly.

InSync Sentry CRT-D is an automatic fluid status monitor, which can be programmed to alert patients and clinicians to changes in fluid accumulation in the lungs and thoracic cavity. When used with other standard clinical assessments, this indicator offers the potential for early warning of fluid accumulation and appropriate clinical response. Approximately 22 million people worldwide have heart failure, of which approximately 5 million are likely to be in India. Of these 5 million patients, approximately 450,000 are likely to have moderate to severe heart failure with ventricular dysynchrony and are candidates for cardiac resynchronisation therapy, which helps the heart beat more efficiently.

“All the devices have gone through European clinical evaluation and the Physicians who participated have seen significant benefits for all products,” said Milind Shah, managing director, India Medtronic, at a press conclave in Bangalore.

Medtronic, Inc., headquartered in Minneapolis, is the world’s leading medical technology company, providing lifelong solutions for people with chronic disease.